Griffith DE, Thomson R, Addrizzo-Harris DJ, et al. Sustainability and durability of culture conversion in patients receiving amikacin liposome inhalation suspension (ALIS) for treatment-refractory mycobacterium avium complex lung disease (MAC-LD) in the CONVERT Study. Am J Resp Crit Care Med. 2019;199:A7358.
Pembrolizumab bij patiënten met NSCLC en performance status 2
mei 2020 | Immuuntherapie, Longoncologie